The comprehensive evaluation of the immunometabolic phenotype of tumour microenvironment in breast cancer.
Investigation of the underlying biology and immunomodulatory effects of anti-PD1 and metformin combination using targeted transcriptomics and multiplex immunohistochemistry in a breast tumour murine model.
David’s current research interests focus on indirect treatment comparisons and early health technology assessment (HTA) modelling.
He specialises in the application and development of methodologies for indirect treatment comparisons of treatments not directly compared in clinical trials. David has taught training courses and published numerous academic papers in this field. Furthermore, he leads SHTAC’s evaluation of meta-analysis and indirect treatment comparison components of company submissions to NICE as part of the TAR programme.
David’s work in early health technology assessment focuses on medical devices and digital technologies (MedTech). He is currently supporting several academic and industry partners in their paths to reimbursement. David enjoys collaborating with multidisciplinary teams to develop research proposals. He has built decision-analytic models to evaluate cost-effectiveness and conducted value of information (VOI) analyses to inform future research priorities.
